Status:
ACTIVE_NOT_RECRUITING
First-in-Human (FIH) Study of the Xeltis Hemodialysis Access Graft
Lead Sponsor:
Xeltis
Conditions:
End Stage Renal Disease
End Stage Renal Failure on Dialysis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A feasibility study is to assess the preliminary safety and performance of the Xeltis hemodialysis access (aXess) graft.
Detailed Description
A prospective, single arm, non-randomized FIH feasibility study to evaluate the preliminary safety and performance of the Xeltis hemodialysis access graft in subjects older than 18 years with end-stag...
Eligibility Criteria
Inclusion
- Subjects older than 18 years with end-stage renal disease (ESRD) who are not, or who are no longer, candidates for creation of an autogenous AV fistula, and therefore require placement of an AV graft in the upper extremity to start or maintain hemodialysis therapy
- Suitable anatomy for the implantation of an aXess graft
- The patient has been informed about the nature of the study, agrees to its provisions, and has provided written informed consent
- The patient has been informed and agrees to pre- and post- procedure follow up
- Life expectancy of at least 12 months
Exclusion
- History or evidence of severe cardiac disease (NHYA Functional Class IV and/or EF \<30%), myocardial infarction within six months of study entry, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina
- Stroke within six months before study entry
- Active clinically significant autoimmune / inflammatory disease, immunodeficiency (including AIDS / HIV), use of immunosuppressive therapy or medication that likely interferes with restorative therapies
- Abnormal blood values (e.g. leurkopenia with white blood cell (WBC) count \< 4,000/mm3 and/or anemia with hemoglobin \<8g/dL and/or thrombocytopenia \< 100,000/mm3) that could influence patient recovery and/or graft hemostasis
- Any active local or systemic infection (WBC \> 15,000/mm3)
- Uncontrolled or poorly controlled diabetes (hemoglovin A1c \> 8% despite standard care) or hospitalization for poor glucose control within the previous 6 months
- Reduced liver function, defined as: \>2x the upper limit of normal for serum bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase; International Normalized Ratio (INR) \> 1.5 or prothrombin time (PT) \> 18 seconds
- Known heparin-induced thrombocytopenia
- Active bleeding disorder and/or any coagulopathy or thrombo embolic disease
- History or evidence of severe peripheral vascular disease in the upper limbs
- Known or suspected central vein obstruction on the side of planned graft implantation
- Previous dialysis access graft in the operative limb unless the aXess graft can be placed more proximally than the previous failed graft
- More than 1 failed dialysis access graft in the operative limb
- Anticipated renal transplant within 6 months
- Subjects receiving a forearm graft which crosses the elbow
- Allergies to study device (Nitinol) or agents/medication, such as contrast agents, aspirin, or clopidogrel, that cant be controlled medically
- Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives
- Subject is participating in another study
- Previous enrollment in this study
- Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and efficacy of the study conduit
Key Trial Info
Start Date :
June 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04898153
Start Date
June 10 2021
End Date
September 1 2027
Last Update
July 10 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
A.Z. Sint Jan
Bruges, Belgium
2
Ziekenhuis Oost-Limburg
Genk, Belgium
3
UZ Ghent
Ghent, Belgium
4
Universita degli studi dell'Insubria
Varese, Italy